The ABL2 Knockout HeLa Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the ABL2 gene, providing a heterogeneous loss-of-function model for biomedical research. This polyclonal knockout cell population is generated without single-cell cloning, maintaining a mixed genotype that more closely reflects the variability observed in physiological and pathological contexts. The product is designed for investigating the molecular and cellular consequences of ABL2 ablation in a well-characterized cervical adenocarcinoma background, and is suitable for a wide range of functional assays requiring gene disruption rather than complete gene deletion.
HeLa cells are a widely utilized human epithelial cell line derived from a cervical adenocarcinoma, persistently infected with human papillomavirus type 18 (HPV18). These cells exhibit robust proliferation, aneuploidy, and invasive properties, making them a standard model for studying cancer cell biology, metastasis, and viral oncogenesis. Their well-documented signaling networks and adaptability to genetic manipulation render them an ideal host for loss-of-function studies. The HPV18-positive status also adds relevance to studies exploring viral?Chost interactions and their impact on cytoskeletal dynamics and tumor progression.
ABL2 (also known as ARG) encodes a non-receptor tyrosine kinase that operates downstream of cell surface receptors including PDGFR and Eph receptors, as well as integrin and chemokine receptor activation. It directly phosphorylates and interacts with cortactin, Crk adaptor proteins, and Nck, linking receptor signals to the WAVE complex and Rho family GTPases such as Rac. This mediates actin polymerization and branching through the PDGFR?CABL2?CCrk?CRac?CWAVE?CArp2/3 axis and the Eph receptor?CABL2?Ccortactin pathway. ABL2 also modulates STAT3 and JNK signaling, integrating cytoskeletal reorganization with transcriptional responses. Consequently, ABL2 is a central node in cell adhesion, migration, and invasion, with its activity tightly regulated by upstream stimuli.
In the HeLa host, ABL2 disruption attenuates actin cytoskeleton remodeling and impairs the pro-migratory and pro-invasive signaling programs essential for metastatic behavior. The polyclonal nature introduces genetic heterogeneity, allowing researchers to dissect how variable ABL2 expression levels influence phenotypic outcomes and to model the stochastic nature of gene loss in tumor cell populations. This model is particularly relevant for studying HPV-driven carcinogenesis, where tyrosine kinase signaling cooperates with viral oncoproteins to promote malignancy. By sidestepping clonal artifacts, the polyclonal population provides a more robust platform for investigating cancer cell plasticity and drug resistance mechanisms.
Research applications encompass cancer metastasis research, cytoskeleton dynamics study, drug resistance mechanism studies, and tyrosine kinase signaling pathway analysis. The cells can be employed in western blotting and RT-qPCR to confirm protein and mRNA changes, immunofluorescence to visualize focal adhesions and actin structures, wound healing assays to measure collective migration, and Transwell invasion assays to quantify invasiveness. Phospho-tyrosine profiling can further elucidate altered signaling networks. For further technical specifications or to inquire about custom cell engineering services, please contact Ascent Research.
